Article ID Journal Published Year Pages File Type
3992607 Journal of Thoracic Oncology 2008 9 Pages PDF
Abstract
Carboplatin, paclitaxel, and irinotecan with concurrent chemoradiotherapy was poorly tolerated as a result of neutropenia. Although dose de-escalation was required for delivery of the regimen, the response rates and survival outcomes were comparable to other similar regimens.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Oncology
Preview
Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung Cancer
Authors
, , , , , , , , , , , ,